This consistent expression pattern—observed in both patient lung tissues and fibrotic injury models—strongly supports a potential regulatory role for YBX1 in IPF pathogenesis and highlights its value as a prospective diagnostic biomarker or therapeutic target. Here, YBX1 is linked to idiopathic pulmonary fibrosis.